Trial · NCT07136285
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
NCT07136285, Phase 1, Phase 2, Recruiting, Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC. Trials, record NCT07136285. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07136285
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
- NCT number
- NCT07136285
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 27 participants, estimated
- Lead sponsor
- Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
- Conditions
- SCLC, Extensive Stage
- Interventions
- Olvi-Vec, platinum (cisplatin or carboplatin), Etoposide
- First posted
- 2025-08-22
- Last updated
- 2025-12-03
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate safety of Olvi-Vec in patients from day 1 to end of study | Interval between the date of enrollment and the date of withdraw and completion of study, up to a maximum of 2 years. | Frequency and severity of adverse events measured according to NCI Common Toxicity Criteria Adverse Event (CTCAE), version 5.0 |
| Secondary | Explore the dose limiting toxicity (DLTs) during day 1 to day 25 of treatment cycle 1 | Day 1 to day 25 of treatment cycle 1 | Olvi-Vec related Grade 3 or higher adverse events (AEs) which meets DLT criteria. |
| Secondary | Objective Response Rate (ORR) | Interval between the date of enrollment and the date of withdraw and completion of study, up to a maximum of 2 years. | ORR is proportion of subjects with complete response(CR) or partial response(PR). Tumor responses will be evaluated according to RECIST 1.1 criteria. Patients with no tumor assessment after baseline will be classified as non-responders. |
| Secondary | Disease control rate (DCR) | Interval between the date of enrollment and the date of withdraw and completion of study, up to a maximum of 2 years. | DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST V1.1 |
| Secondary | Progression free survival (PFS) | Interval between the date of enrollment and the date of withdraw and completion of study, up to a maximum of 2 years. | PFS is defined as the time from the date of first dosing till the first documentation of disease progression (per RECIST v1.1) assessed by the investigator or death due to any cause (whichever occurs first) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07136285
GET https://conductscience.org/api/trials/v1/NCT07136285/registered